DASHER NEUROSCIENCE
Live / Applied — Response to non-final action entered (as of 05 Oct 2026)
What this means for you
Not registered yet, but its 22 Apr 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99780347
- Mark type
- Word mark
- Filed
- 22 Apr 2026
- Attorney of record
- Michael T. Smith
Goods and services
- Class 005 — Pharmaceuticals: Chemical preparations for pharmaceutical purposes, namely, for the treatment or prevention of neurodegenerative or neurodevelopmental diseases and disorders; Anti-inflammatory agents; Pharmaceutical anti-allergic preparations and substances; Antidepressants; Anti-epiletic pharmaceutical preparations; Flour for pharmaceutical purposes; Medicinal preparations for the mouth and as sprays; Chemical preparations for pharmaceutical purposes, namely, for the treatment or prevention of multiple system atrophy, Parkinson's disease, Alzheimer's disease, or schizophrenia; Active pharmaceutical ingredients for chemical preparations for pharmaceutical or medical purposes, namely, for the treatment or prevention of neurodegenerative or neurodevelopmental diseases and disorders; Active pharmaceutical ingredients for chemical preparations for pharmaceutical or medical purposes, namely, for the treatment or prevention of multiple system atrophy, Parkinson's disease, Alzheimer's disease, or schizophrenia; Neuroleptic agents being pharmaceutical preparations for the treatment or prevention of neurodegenerative or neurodevelopmental diseases and disorders; Neuroleptic agents being pharmaceutical preparations for the treatment or prevention of multiple system atrophy, Parkinson's disease, Alzheimer's disease, or schizophrenia; Medicinal agents being chemical preparations for pharmaceutical or medical purposes, namely, for the treatment or prevention of neurodegenerative or neurodevelopmental diseases and disorders; Medicinal agents being chemical preparations for pharmaceutical or medical purposes, namely, for the treatment or prevention of multiple system atrophy, Parkinson's disease, Alzheimer's disease, or schizophrenia; Nervines being chemical preparations for pharmaceutical or medical purposes, namely, for the treatment or prevention of neurodegenerative or neurodevelopmental diseases and disorders; Nervines being chemical preparations for pharmaceutical or medical purposes, namely, for the treatment or prevention of multiple system atrophy, Parkinson's disease, Alzheimer's disease, or schizophrenia; Chemical preparations for medical purposes, namely, for the treatment or prevention of neurodegenerative or neurodevelopmental diseases and disorders; Chemical preparations for medical purposes, namely, for the treatment or prevention of multiple system atrophy, Parkinson's disease, Alzheimer's disease, or schizophrenia; Medicinal drinks; Chemico-pharmaceutical preparations for pharmaceutical or medical purposes, namely, for the treatment or prevention of neurodegenerative or neurodevelopmental diseases and disorders; Chemico-pharmaceutical preparations for pharmaceutical or medical purposes, namely, for the treatment or prevention of multiple system atrophy, Parkinson's disease, Alzheimer's disease, or schizophrenia; Pharmaceutical drugs for the treatment or prevention of neurodegenerative or neurodevelopmental diseases and disorders; Pharmaceutical drugs for the treatment of or prevention of multiple system atrophy, Parkinson's disease, Alzheimer's disease, or schizophrenia; Pharmaceutical preparations for the treatment or prevention of neurodegenerative or neurodevelopmental diseases and disorders; Pharmaceutical preparations for the treatment or prevention of multiple system atrophy, Parkinson's disease, Alzheimer's disease, or schizophrenia; Lozenges for pharmaceutical purposes, namely, for the treatment or prevention of neurodegenerative or neurodevelopmental diseases and disorders; Lozenges for pharmaceutical purposes, namely, for the treatment or prevention of multiple system atrophy, Parkinson's disease, Alzheimer's disease, or schizophrenia; Chemical reagents for medical purposes; Bronchodilating preparations; Pharmaceutical preparations for treating asthma; Inhalants for the treatment of respiratory conditions; Analgesics; Anti-inflammatories; Anti-inflammatory and analgesic agents; Muscle relaxants; Biological preparations for use in cell cultures for medical purposes; Antidiabetic preparations; Medical preparations for slimming purposes; Slimming pills; Appetite suppressants for medical purposes; Appetite suppressant pills; Pre-filled syringes for medical purposes, namely, for the treatment or prevention of neurodegenerative or neurodevelopmental diseases and disorders; Pre-filled syringes for medical purposes, namely, for the treatment or prevention of multiple system atrophy, Parkinson's disease, Alzheimer's disease, or schizophrenia; Food supplements, namely, antioxidant pills
Owner
- DASHER NEUROSCIENCE INC., Taipei City 115, TW
Prosecution history
- 05 Oct 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 05 Oct 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 05 Oct 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 22 Jul 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 22 Jul 2026 — NON-FINAL ACTION E-MAILED
- 22 Jul 2026 — NON-FINAL ACTION WRITTEN
- 21 Jul 2026 — ASSIGNED TO EXAMINER
- 22 Apr 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 22 Apr 2026 — APPLICATION FILING RECEIPT MAILED
- 22 Apr 2026 — NEW APPLICATION ENTERED